WASHINGTON (Legal Newsline) — The Federal Trade Commission (FTC) has approved a modified final order that settles anti-competitive allegations for Hikma Pharmaceuticals PLCS’s $2 billion acquisition of Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc.

To complete the acquisition under terms of the order, Hikma must divest the rights and assets for two generic drugs, prednisone tablets and lithium carbonate capsules, to Pennsylvania-based Renaissance Pharma Inc.

Additionally, Hikma is required to relinquish the rights to market flecainide acetate tablets in the United States to India-based Unimark Remedies Ltd., its drug development partner. Hikma will also divest equity interest in Unimark, the FTC said.

The FTC voted 3-0 to approve the modified final order.

Want to get notified whenever we write about U.S. Federal Trade Commission ?
Next time we write about U.S. Federal Trade Commission , we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

U.S. Federal Trade Commission

More News